Turkish experience in rheumatoid arthritis patients with clinical apparent amyloid deposition

dc.authoridPuyan, Fulya/0000-0001-5853-0109
dc.authoridOz Puyan, Fulya/0000-0001-5853-0109
dc.authorwosidPuyan, Fulya/V-7074-2019
dc.authorwosidOz Puyan, Fulya/A-7077-2018
dc.contributor.authorPamuk, Omer Nuri
dc.contributor.authorDonmez, Salim
dc.contributor.authorPamuk, Gulsum Emel
dc.contributor.authorPuyan, Fulya Oz
dc.contributor.authorKeystone, Edward C.
dc.date.accessioned2024-06-12T10:50:13Z
dc.date.available2024-06-12T10:50:13Z
dc.date.issued2013
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives: We evaluated the frequency of clinical apparent amyloid deposition, clinical features and outcome in our rheumatoid arthritis (RA) patients. Methods: Medical records of 1415 RA patients were examined. During routine follow-up, RA patients with proteinuria on urinalysis, underwent rectal biopsy. Results: Eleven patients (0.78%) were diagnosed with clinical apparent amyloid deposition. While the mean annual incidence of AA amyloidosis between 2001 and 2005 was 0.2%, it was 0.13% between 2006 and 2011. At initial presentation, three RA-related AA amyloidosis patients had nephrotic-range proteinuria and renal insufficiency, four had only nephrotic-range proteinuria, three had non-nephrotic-range proteinuria, and one had non-nephrotic-range proteinuria and renal insufficiency. The mean age in RA patients with AA amyloidosis was 60.8 years and disease duration was 12 years. Ten of 11 cases had positive rheumatoid factor. Two RA patients with AA amyloidosis who had been diagnosed in the pre-anti-TNF era died. Of the rest nine patients with AA amyloidosis, eight were administered anti-TNF therapy and one was given rituximab. In four patients, anti-TNF therapy led to disappearance of clinical features, decrement in proteinuria and resulted in improvement of or at least stabilization of renal functions. One patient using anti-TNF therapy died because of tuberculosis. One patient discontinued anti-TNF therapy and developed end-stage renal disease. Two patients have been started to be given anti-TNF therapy recently. In one patient who was given rituximab, there was regression of proteinuria and improvement in renal functions. Conclusions: We diagnosed a 0.78% frequency of AA amyloidosis in RA. It seems that - other than the risks of infection, tuberculosis - anti-TNF drugs seem to be effective on RA disease activity and also have renoprotective effects in RA patients with AA amyloidosis.en_US
dc.identifier.doi10.3109/13506129.2013.840576
dc.identifier.endpage250en_US
dc.identifier.issn1350-6129
dc.identifier.issn1744-2818
dc.identifier.issue4en_US
dc.identifier.pmid24106838en_US
dc.identifier.scopus2-s2.0-84888063386en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage245en_US
dc.identifier.urihttps://doi.org/10.3109/13506129.2013.840576
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17920
dc.identifier.volume20en_US
dc.identifier.wosWOS:000327304800007en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherInforma Healthcareen_US
dc.relation.ispartofAmyloid-Journal Of Protein Folding Disordersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAA Amyloidosisen_US
dc.subjectAnti-TNF Therapyen_US
dc.subjectRenal Diseaseen_US
dc.subjectRheumatoid Arthritisen_US
dc.subjectAa Amyloidosisen_US
dc.subjectSecondary Amyloidosisen_US
dc.subjectFollow-Upen_US
dc.subjectDiseasesen_US
dc.subjectSerumen_US
dc.subjectEtanercepten_US
dc.subjectInfliximaben_US
dc.subjectResolutionen_US
dc.subjectEfficacyen_US
dc.subjectTherapyen_US
dc.titleTurkish experience in rheumatoid arthritis patients with clinical apparent amyloid depositionen_US
dc.typeArticleen_US

Dosyalar